Introduction
============

In patients with COPD, the diaphragm is exposed to a chronically increased work load, due to several factors including airflow obstruction and geometrical changes of the thorax derived from pulmonary hyperinflation. As a result, several adaptations occur in diaphragm muscle, eg, a shift towards type I fibers, an increase in oxidative enzyme activity ([@b20-copd-1-173]), loss of fiber myosin heavy chain content, and reduced in vitro force generation ([@b22-copd-1-173]).

In rat diaphragm, in vitro studies have shown that the production of reactive oxygen species (ROS) is enhanced with increased contractile activity ([@b24-copd-1-173]; [@b25-copd-1-173]; [@b15-copd-1-173]). ROS are required for optimal contractile function ([@b24-copd-1-173]), but overproduction of ROS may result in a disturbance between the pro-oxidant and antioxidant balance in favor of the former. The resulting so-called oxidative stress is associated with impaired force generation of skeletal and respiratory muscle in animal models ([@b15-copd-1-173]; [@b25-copd-1-173]). In line with these observations, in vitro force generation of the emphysematous hamster diaphragm is inversely correlated with glutathione oxidation in the diaphragm ([@b9-copd-1-173]).

Oxidative stress has been implicated in the involvement in muscle dysfunction of the quadriceps of COPD patients ([@b4-copd-1-173]). When a muscle is chronically exposed to oxidants, which can be hypothesized to occur in the diaphragm of patients with COPD, it may be expected that this chronic exposure provokes an increase in antioxidant defense. Whether this occurs in the diaphragm of patients with COPD is unknown. However, exercise training in healthy subjects, a condition known to enhance skeletal muscle ROS generation, has been shown to upregulate skeletal muscle antioxidant enzymes including superoxide dismutase ([@b40-copd-1-173]).

In addition to ROS, nitric oxide (NO) has been shown to modulate muscle performance (for a review, see [@b26-copd-1-173]). NO is produced in skeletal muscle fibers by NO synthases (NOS). The main source of NO synthesis is the neuronal (nNOS) isoform, which is localized in close proximity to the sarcolemma ([@b14-copd-1-173]). There is increasing evidence that NO plays a role in regulating muscle glucose uptake ([@b27-copd-1-173]), sarcoplasmic Ca^2+^ release ([@b30-copd-1-173]), and blood flow ([@b11-copd-1-173]). Excessive NO production inside skeletal muscle fibers, however, exerts deleterious effects on sarcolemmal integrity and contractile function ([@b29-copd-1-173]). NO can react with the superoxide anion (·O~2~^−^) to form the highly reactive oxidant peroxynitrite (·ONOO) (for a review see [@b5-copd-1-173]). Peroxynitrite modifies protein tyrosine residues to create 3-nitrotyrosine (NT).

Recently, [@b3-copd-1-173] observed increased oxidative stress as measured by 4-hydroxy-2-nonenal (HNE) levels and protein carbonyl groups, but unchanged 3-NT levels in the diaphragm of moderate and severe COPD patients. In contrast, in a pilot report ([@b36-copd-1-173]) we showed that NT levels were higher in the diaphragm of COPD patients, whereas the level of HNE was not changed. The present study extended the data of this pilot study. Specifically, we hypothesized that in the diaphragm of COPD patients: (1) The activity of antioxidant enzymes is increased; (2) Indirect markers for ROS production and reactive nitrogen species (RNS) production are elevated; and (3) These changes are related to the severity of hyperinflation. To test these hypotheses, we determined catalase activity as a marker for antioxidative capacity, levels of lipid peroxidation as a marker for oxidative stress, and NT formation as a marker for RNS production.

Methods
=======

Subjects
--------

Diaphragm muscle biopsies were obtained from subjects undergoing thoracotomy for lung cancer or lung volume reduction surgery. These patients were divided into 3 groups: non-COPD (n = 15; mean FEV~1~ = 110 ± 3 % predicted), mild-to-moderate COPD (n = 17; mean FEV~1~ = 67 ± 3% predicted). and severe COPD (n = 7; mean FEV~1~ = 37 ± 5% predicted). General characteristics and pulmonary function data are shown in [Table 1](#t1-copd-1-173){ref-type="table"}. Informed consent was obtained from each of the subjects, and the study was approved by the ethical committee of our hospital.

Biopsy handling
---------------

Biopsies were immediately cut into 2 pieces. One part was directly frozen in liquid nitrogen for biochemical determinations. The remaining part was directly frozen in isopentane precooled by liquid nitrogen for immunohistochemistry. Both samples were stored at −80°C until further analysis. Due to limitation of the biopsy size, all the biochemical determinations could not be performed in each patient.

Catalase activity determination
-------------------------------

Fresh frozen biopsies were thawed in ice-cooled buffer containing 250 mM sucrose, 2 mM EDTA, and 10 mM Tris-HCl (pH 7.4). In this buffer muscle homogenates (5% wt/vol) were prepared using a Potter-Elvehjem glass-teflon homogenizer. The catalase activity was measured using the method of [@b1-copd-1-173]. Briefly, the above-mentioned homogenates were used, and H~2~O~2~ decomposition was measured spectrophotometrically. The difference in absorbance (ΔA~240~) per minute was a measure of the catalase activity. The assay was performed in duplicate.

Immunoblotting
--------------

NT formation was detected using western immunoblotting with a monoclonal anti-NT antibody (clone 1A6; Upstate Biotechnology Inc, Lake Placid, NY, USA), as published previously ([@b39-copd-1-173]). Briefly, crude muscle homogenate proteins (10 μg) were separated by electrophoresis (100 V for 1 hour) on 10% sodium dodecylsulfate polyacrylamide gels. Proteins were transferred electrophoretically (100 V, 300 mA for 1.5 hours) to nitrocellulose membranes. The nitrocellulose membranes were subsequently incubated with primary monoclonal antibodies against NT. After a washing step, the nitrocellulose membranes were incubated with a secondary antibody (polyclonal anti-mouse IgG horseradish peroxidase conjugated; Pierce, Rockford, IL, USA). After a second washing step, protein bands were visualized using an enhanced chemiluminescence detection kit (Amersham Biosciences Europe GmbH, The Netherlands). The blots were scanned with an imaging densitometer and optical densities (OD) of positive NT protein bands were quantified with GeneTools software (Syngene, UK). Total NT OD was calculated for each sample by adding OD of individual positive protein bands.

HNE was detected with the same method as NT, with a few alterations. The primary antibody was a polyclonal rabbit antibody against 4-hydroxy-2-nonenal (Calbiochem, San Diego, CA, USA). The secondary antibody was a polyclonal anti-rabbit IgG antibody (polyclonal anti-rabbit IgG horseradish peroxidase conjugated; Pierce, Rockford, IL, USA).

Immunohistochemistry
--------------------

A polyclonal rabbit antibody against 4-hydroxy-2-nonenal used (Calbiochem, San Diego, CA, USA). NT was detected with a polyclonal rabbit anti-NT antibody (Upstate Biotechnology Inc., Lake Placid, NY, USA). Tissue sections (5 μm) were incubated with the antibodies in 0.5% (w/v) BSA in PBS with 0.05% Tween-20 (BSA/PBST) for 60 minutes. Bound antibodies were detected using Alexa-labelled (488) anti-rabbit antibodies. Finally, tissue sections were fixed in methanol, air-dried, and embedded in mowiol (10% \[w/v\] in 0.1 M Tris-HCl, pH 8.5, 25% \[v/v\] glycerol), and 2.5% \[w/v\] NaN~3~). As a control, primary antibodies were omitted.

Malondialdehyde determination
-----------------------------

Malondialdehyde (MDA) levels were assessed by high-performance liquid chromatography, as previously reported ([@b38-copd-1-173]; [@b39-copd-1-173]). Muscle samples (40 mg) were homogenized and centrifuged, and the supernatants were collected and stored on ice. Samples were hydrolyzed by boiling in diluted phosphoric acid. MDA, one of the low-molecular-weight end products formed via the decomposition of lipid-peroxidation products, was reacted with thiobarbituric acid (TBA) to form MDA-TBA adducts ([@b12-copd-1-173]). The adduct was eluted from the column with methanol-phosphate buffer and quantified spectrophotometrically at 532 nm.

Statistical analysis
--------------------

Data are presented as mean ± standard error of the mean (SEM) when appropriate. Data were analyzed with SPSS for Windows^®^, version 12.0.1. A oneway ANOVA test was used to compare results between groups. To establish the relationship between the oxidative stress parameters and lung function, Pearson correlation was determined. Significance was set at the 0.05 level.

Results
=======

Patient characteristics
-----------------------

Patient characteristics are shown in [Table 1](#t1-copd-1-173){ref-type="table"}. The patients with COPD did not differ significantly from the non-COPD patients with respect to age and body mass index (BMI).

Catalase activity
-----------------

Diaphragm muscle catalase activity was significantly higher in severe COPD patients (n = 3) compared with both non-COPD patients (n = 5) and with patients with mild-to-moderate COPD (n = 5) ([Figure 1](#f1-copd-1-173){ref-type="fig"}).

NT formation
------------

Diaphragm muscle NT level was assessed as a marker for peroxynitrite formation. As illustrated in [Figure 2](#f2-copd-1-173){ref-type="fig"}, no difference was found in muscle protein nitration between the groups (non-COPD: n = 7, mild-to-moderate COPD: n = 6, severe COPD: n = 3). Among all COPD patients, significant negative correlations were found between muscle protein nitration and total lung capacity (TLC) (r = −0.797, p = 0.018), TLC% predicted (r = −0.85, p = 0.007), and FRC% predicted (r = −0.85, p = 0.008). Immunofluorescence analysis showed positive staining for NT localized within the muscle fibers in both COPD patients and non-COPD patients, with some fibers staining more intensely than other fibers ([Figure 3](#f3-copd-1-173){ref-type="fig"}).

Lipid peroxidation
------------------

[Figure 4](#f4-copd-1-173){ref-type="fig"} shows the effect of COPD on markers for lipid peroxidation in the diaphragm. HNE-protein adduct formation was not significantly different between severe COPD (n = 2), mild-to-moderate COPD (n = 6), and non-COPD patients (n = 7). No relationship was found between HNE-protein adducts and severity of hyperinflation in the COPD group. Immunofluorescence analysis showed positive staining for HNE-protein adducts localized within the muscle fibers in both COPD patients and non-COPD patients ([Figure 5](#f5-copd-1-173){ref-type="fig"}).

Diaphragm MDA level was significantly lower in mild-to-moderate COPD patients (n = 6) compared with non-COPD patients (n = 3). MDA level in severe COPD patients (n = 2) tended to be lower than in non-COPD patients.

Discussion
==========

Our results demonstrate that in the diaphragm of COPD patients, catalase activity is increased and lipid peroxidation is decreased. Furthermore, with increasing severity of hyperinflation, the level of protein tyrosine nitration is reduced.

Oxidative and nitrosative stress may be expected to occur in the diaphragm of COPD patients. Firstly, antioxidative capacity may be altered. In this study, we found that the activity of catalase is increased in the diaphragm of COPD patients. This finding is in accordance with the increase in diaphragmatic antioxidant capacity after endurance training in rats ([@b34-copd-1-173]) and mice ([@b28-copd-1-173]), and in line with progressive endurance training of the human diaphragm due to increased load over several decades ([@b19-copd-1-173]). [@b3-copd-1-173] reported a tendency towards a decrease in catalase *protein content* with increasing severity of hyperinflation. However, catalase protein content is not directly related to catalase activity ([@b37-copd-1-173]), so our findings do not necessarily contrast with the findings by Barreiro et al.

Secondly, alterations in the level of nitrotyrosines, a marker for peroxynitrite generation, may occur. Peroxynitrite is a reaction product of NO and ·O~2~^−^ . In contrast to our hypothesis, NT level was decreased with increasing severity of hyperinflation. In rat gastrocnemius muscle, endurance training increases NT formation ([@b33-copd-1-173]). A possible explanation is that the activity of, eg superoxide dismutase (SOD), may also be increased in the diaphragm of COPD patients, since training-induced increases in SOD activity have been reported in rat vastus lateralis ([@b16-copd-1-173], [@b17-copd-1-173]). This increase might decrease levels of ·O~2~^−^, leading to decreased peroxynitrite formation and thus lower NT levels.

Another consequence of an alteration in redox state that may occur in the diaphragm of COPD patients, is a change in lipid peroxidation. In this study, we found a decreased level of MDA in the diaphragm of COPD patients, but no change in HNE-protein adduct formation, which is most likely related to the small sample size. The determination of MDA and HNE are different methods, based on different principles. HNE is recognized as the most reliable marker of lipid peroxidation ([@b32-copd-1-173]; [@b31-copd-1-173]), but the number of measurements in severe COPD patients was low. For determination of MDA, we used a specific, sensitive, and reproducible HPLC method that allows a good separation between the MDA-TBA and interfering substances ([@b38-copd-1-173]). The reduced MDA levels observed in our study strongly indicate that enhanced lipid peroxidation occurs in the diaphragm of COPD patients. Since the diaphragm of COPD patients shows endurance training-like alterations ([@b20-copd-1-173]), we suggest that the lower level of lipid peroxidation also resembles the effect of endurance training. Indeed, the decreased level of lipid peroxidation in our study is in accordance with studies in skeletal muscle after endurance training in mice ([@b28-copd-1-173]) and in diaphragm muscle of endurance-trained rats ([@b34-copd-1-173]).

In contrast to the reduced lipid peroxidation in diaphragm muscle of COPD patients, lipid peroxidation seems to be increased in peripheral muscle of COPD patients. For example, [@b2-copd-1-173] found an increase in lipofuscin content, a marker for oxidative damage to lipids, in quadriceps muscle of COPD patients. This finding contrasts with those of other studies ([@b23-copd-1-173]; [@b7-copd-1-173]), reporting equal levels of lipid peroxidation in vastus lateralis muscle of resting COPD patients as compared with controls, evaluated by the concentration of thiobarbituric acid reactive substances (TBARs). This discrepancy may be explained by different methods that were used to assess lipid peroxidation; whereas TBARs are markers of acute oxidative stress, lipofuscin, which accumulates in the cells, is a reflector of cumulative stress. Moreover, the latter study ([@b7-copd-1-173]) reported an increase in lipid peroxidation after an exercise bout in vastus lateralis of COPD patients. Furthermore, glutathione peroxidase activity in vastus lateralis muscle of healthy subjects was increased after a single bout of exercise, whereas the antioxidant activity of COPD patients was not changed. This indicates that vastus lateralis muscle of COPD patients is more vulnerable to oxidative stress as a result of a compromised exercise-induced increase in antioxidative function. Besides determination of lipid peroxidation in the muscle, plasma lipid peroxidation can be used as a marker for free radical-induced tissue damage. We ([@b10-copd-1-173]) reported previously that in rest there was no difference in serum MDA level between COPD patients receiving the xanthine oxidase inhibitor allopurinol and control COPD patients. However, after exhaustive exercise, MDA levels were significantly higher in the control COPD subjects, suggesting that during exercise lipid peroxidation occurs, which can be attenuated by treatment with allopurinol.

In the diaphragm of COPD patients a shift occurs from type II to type I fibers ([@b18-copd-1-173]) and it has been previously shown that type I fibers are more susceptible to lipid peroxidation ([@b2-copd-1-173]). However, in our study we have shown decreased lipid peroxidation levels in the diaphragm of COPD patients. This might be explained by the finding that antioxidative capacity is increased, thereby protecting the muscle fibers against lipid peroxidation. In contrast, in peripheral muscles of COPD patients a shift occurs towards type II fibers ([@b21-copd-1-173]; [@b35-copd-1-173]; [@b8-copd-1-173]), having a lower antioxidant capacity than type I fibers ([@b6-copd-1-173]; [@b13-copd-1-173]). This may explain the fact that in peripheral skeletal muscles of COPD patients more lipid peroxidation is observed, although the exact relationship between fiber type composition and antioxidant capacity remains to be elucidated in COPD. These findings together suggest that the disuse of peripheral muscles in COPD results in enhanced lipid peroxidation, whereas the chronically increased loading on the diaphragm in COPD results in a decrease in lipid peroxidation.

In summary, this study shows that in the diaphragm of COPD patients, catalase activity as a marker for antioxidant capacity is increased, associated with a decrease in oxidative and nitrosative stress. From a clinical perspective, this adaptation may be beneficial for diaphragm function, as it has been shown that oxidative stress is associated with muscle dysfunction.

![Catalase activity (mean ± SEM) in diaphragms of non-COPD patients and both mild-to-moderate and severe COPD patients. Catalase activity was significantly elevated in the diaphragm of severe COPD patients.\
^a^p \< 0.05 vs non-COPD patients; ^b^p \< 0.05 vs mild-to-moderate COPD patients.](copd-1-173f1){#f1-copd-1-173}

![(a) 3-Nitrotyrosine (NT) optical density (OD) (mean ± SEM) in diaphragms of non-COPD patients and both mild-to-moderate and severe COPD patients. NT levels were not different between the three groups.\
(b) Relationship between total lung capacity (TLC) % predicted and NT OD in all COPD patients (r = −0.853, p = 0.007).](copd-1-173f2){#f2-copd-1-173}

![Immunofluorescence analysis of 3-nitrotyrosine localization in diaphragm muscle of 1 representative non-COPD patient (a) and 1 representative severe COPD patient (b). The staining is localized diffusely within the muscle fibers, with some fibers staining more intensely than other fibers. Scale bar = 100 μm.](copd-1-173f3){#f3-copd-1-173}

![(a) 4-Hydroxy-2-nonenal (HNE) optical density (OD) (mean ± SEM) in diaphragms of non-COPD patients and both mild-to-moderate and severe COPD patients. HNE-protein adduct levels were not different between the three groups. (b) Malondialdehyde (MDA) levels (mean ± SEM) in diaphragms of non-COPD patients and both mild-to-moderate and severe COPD patients. MDA levels were significantly lower in diaphragms of mild-to-moderate COPD patients (^a^p \< 0.05) and tended to be lower in severe COPD patients (p = 0.06).](copd-1-173f4){#f4-copd-1-173}

![Immunofluorescence analysis of 4-hydroxy-2-nonenal-protein adduct localization in diaphragm muscle of 1 representative non-COPD patient (a) and 1 representative severe COPD patient (b). The staining is localized diffusely within the muscle fibers, with some fibers staining more intensely than other fibers. Scale bar = 100 μm.](copd-1-173f5){#f5-copd-1-173}

###### 

Patient characteristics

                       Mild-to-moderate                                                             
  -------------------- ------------------ --------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  Age (years)          58 ± 3             63 ±V2                                                    59 ± 4
  BMI (kg/m^2^)        25 ± 1             26 ± 1                                                    23 ± 1
  FEV~1~               3.30 ± 0.13        1.91 ± 0.09 [aa](#tfn3-copd-1-173){ref-type="table-fn"}   1.12 ± 0.19 [aa](#tfn3-copd-1-173){ref-type="table-fn"}[bb](#tfn5-copd-1-173){ref-type="table-fn"}
  FEV~1~ % predicted   110 ± 3            67 ± 3 [aa](#tfn3-copd-1-173){ref-type="table-fn"}        37 ± 5 [aa](#tfn3-copd-1-173){ref-type="table-fn"}[bb](#tfn5-copd-1-173){ref-type="table-fn"}
  FEV~1~/VC            78 ± 1             53 ± 2 [aa](#tfn3-copd-1-173){ref-type="table-fn"}        33 ± 5 [aa](#tfn3-copd-1-173){ref-type="table-fn"}[bb](#tfn5-copd-1-173){ref-type="table-fn"}
  TLC % predicted      103 ± 3            90 ± 5                                                    114 ± 8 [b](#tfn4-copd-1-173){ref-type="table-fn"}
  FRC % predicted      98 ± 19            93 ± 6                                                    130 ± 15 [b](#tfn4-copd-1-173){ref-type="table-fn"}
  K~CO~ % predicted    95 ± 6             76 ± 4 [a](#tfn2-copd-1-173){ref-type="table-fn"}         48 ± 8 [aa](#tfn3-copd-1-173){ref-type="table-fn"}[b](#tfn4-copd-1-173){ref-type="table-fn"}

Values are means ± SEM.

p \< 0.05 and

p \< 0.001 vs non-COPD patients.

p \< 0.05 and

p \< 0.001 between mild-to-moderate COPD and severe COPD patients.

**Abbreviations:** BMI, body mass index; FEV~1~, forced expiratory volume in 1 second; VC, vital capacity; TLC, total lung capacity; K~CO~, diffusion coefficient for carbon monoxide; FRC, functional residual capacity.
